In-Hospital Business was Burning Rock Biotech’s largest segment in fiscal 2025, bringing in $224.04M of $539.57M (42%).
| Segment | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Central Laboratory Business | $314.77M | $232.81M | $175.65M | $159.99M | ||||
| In-Hospital Business | $175.30M | $188.70M | $224.49M | $224.04M | ||||
| Pharma Research & Development Services | $73.17M | $115.92M | $115.68M | $155.54M | ||||
| Total | $563.24M | $537.44M | $515.82M | $539.57M |
Burning Rock Biotech brought in $539.57M from its three segments in fiscal 2025, the year ended December 31, 2025. That was up 4.6% from $515.82M in fiscal 2024. In-Hospital Business was the largest at $224.04M (41.5%), ahead of Central Laboratory Business at $159.99M (29.7%) and Pharma Research & Development Services at $155.54M (28.8%).
Compared with fiscal 2024, Pharma Research & Development Services grew fastest, up 34.5% to $155.54M, while Central Laboratory Business fell the most, down 8.9% to $159.99M. From fiscal 2022 to 2025, combined revenue from these segments fell from $563.24M to $539.57M, a compound annual decline of 1.4%. In-Hospital Business' share of the total rose from 31.1% to 41.5%.
Service was Burning Rock Biotech’s largest product and service line in fiscal 2025, bringing in $316.11M of $539.57M (59%).
| Product and Service | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Service | $391.55M | $345.03M | $290.74M | $316.11M | ||||
| Product | $171.69M | $192.41M | $225.08M | $223.46M | ||||
| Total | $563.24M | $537.44M | $515.82M | $539.57M |
Burning Rock Biotech brought in $539.57M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 4.6% from $515.82M in fiscal 2024. Service was the largest at $316.11M (58.6%), ahead of Product at $223.46M (41.4%).
Compared with fiscal 2024, Service grew 8.7% to $316.11M, while Product fell 0.7% to $223.46M. From fiscal 2022 to 2025, combined revenue from these lines fell from $563.24M to $539.57M, a compound annual decline of 1.4%. Service's share of the total fell from 69.5% to 58.6%.
Chinese Mainland was Burning Rock Biotech’s largest region in fiscal 2025, bringing in $438.64M of $539.57M (81%).
| Geography | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Chinese Mainland | $476.19M | $415.73M | $438.64M |
| Overseas | $61.24M | $100.09M | $100.93M |
| Total | $537.44M | $515.82M | $539.57M |
Burning Rock Biotech brought in $539.57M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 4.6% from $515.82M in fiscal 2024. Chinese Mainland was the largest at $438.64M (81.3%), ahead of Overseas at $100.93M (18.7%).
Compared with fiscal 2024, Chinese Mainland grew 5.5% to $438.64M and Overseas grew 0.8% to $100.93M. From fiscal 2023 to 2025, combined revenue from these regions grew from $537.44M to $539.57M, a compound annual growth rate of 0.2%. Chinese Mainland's share of the total fell from 88.6% to 81.3%.
Burning Rock Biotech (BNR) reports its revenue by segment, by product and service and by geography. In fiscal 2025, In-Hospital Business was its largest segment, bringing in $224.04M (41.5% of the total), followed by Central Laboratory Business at $159.99M (29.7%).
In-Hospital Business was Burning Rock Biotech's largest segment in fiscal 2025, bringing in $224.04M, or 41.5% of the $539.57M total across its three segments.
Service was Burning Rock Biotech's largest product and service line in fiscal 2025, bringing in $316.11M, or 58.6% of the $539.57M total across its two product and service lines.
Chinese Mainland was Burning Rock Biotech's largest region in fiscal 2025, bringing in $438.64M, or 81.3% of the $539.57M total across its two regions.
Among Burning Rock Biotech's segments that make up at least 2% of revenue, Pharma Research & Development Services grew fastest in fiscal 2025, up 34.5% from $115.68M to $155.54M.
Every figure comes from Burning Rock Biotech's annual financial filings, as reported. Each line keeps the name Burning Rock Biotech gives it, and years follow its fiscal calendar.
Burning Rock Biotech's revenue by segment goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.